Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

When he was 25, he learned that he had multiple sclerosis. He coped with the disease throughout a long career at several ...

Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.

The voice of Israeli journalist Moshe Nussbaum has been revived using artificial intelligence after he was diagnosed with ALS.

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...